Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

Objective To provide a meta-level comparison of standardized safety profiles ('gestalt') of currently licensed biologic and targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) in rheumatoid arthritis (RA) from pivotal clinical trials. Methods We systematically searched E...

Descripción completa

Detalles Bibliográficos
Publicado en:Rheumatology Vol. 65; no. 7; pp. 1 - 11
Autores principales: Konzett, Victoria, Kerschbaumer, Andreas, Willmann, Laurenz, Aletaha, Daniel
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Oxford University Press / USA Jul2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195931775&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 195931775
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14620324
        DN9
      jtl: Rheumatology
      issn: 14620324
      maglogo: N
    pubinfo:
      dt: Jul2026
      vid: 65
      iid: 7
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        195931775
        195931775
        195931775
        10.1093/rheumatology/keag263
        195931775
      ppf: 1
      ppct: 10
      formats:
      tig:
        atl: Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.
      aug:
        au:
          Konzett, Victoria
          Kerschbaumer, Andreas
          Willmann, Laurenz
          Aletaha, Daniel
        affil: Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
      sug:
        subj:
          Arthritis, Rheumatoid Drug Therapy
          Antirheumatic Agents Therapeutic Use
          Antirheumatic Agents Adverse Effects
          Biological Products Therapeutic Use
          Biological Products Adverse Effects
          Drug Efficacy
          Patient Safety
          Human
          Male
          Female
          Adult
          Middle Age
          Aged
          Systematic Review
          Meta Analysis
          Embase
          Medline
          Cochrane Library
          Checklists
          Drug Tolerance
          Tumor Necrosis Factor Inhibitors Therapeutic Use
          Interleukins Antagonists and Inhibitors
          Janus Kinase Inhibitors Therapeutic Use
          Herpes Zoster Chemically Induced
          Anaphylaxis Chemically Induced
          Gastrointestinal Diseases Chemically Induced
          Biological Markers
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Objective To provide a meta-level comparison of standardized safety profiles ('gestalt') of currently licensed biologic and targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) in rheumatoid arthritis (RA) from pivotal clinical trials. Methods We systematically searched EMBASE, Medline and the Cochrane Library for randomized controlled RA drug approval trials of bDMARDs and tsDMARDs. The Medical Dictionary for Regulatory Activities (MedDRA) hierarchy system was applied to account for the heterogeneous safety reporting across trials, and random-effects meta-analyses of adverse events (AE) were performed at lower MedDRA levels as well as for major system organ classes. Serious AEs (SAE) and AEs of special interest (AESI) were studied descriptively. Forest plots and radar charts were used for visualization, to generate distinct safety profiles, referred to as 'safety gestalt', for each compound. Results Sixty-four randomized, placebo-controlled drug approval trials were considered, of which 25 studied TNF-α inhibitors, 10 studied IL-6 receptor inhibitors, 5 studied rituximab, 7 studied abatacept and 18 studied Janus kinase inhibitors. Meta-level comparisons of the total number of AEs and SAEs showed comparable overall safety and tolerability, while a more granular insight into distinct organ classes and AESIs disentailed differences between compounds and drug classes. Conclusion Standardized safety reporting and profiling of bDMARDs and tsDMARDs from pivotal clinical drug trials provides an overview of safety outcomes of commonly used RA therapies, supports safety-oriented treatment selection in individual patients, and provides essential context for safety evaluation of novel therapies during periods before long-term safety data become available.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N